Mallinckrodt (NYSE:MNK) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of $1.69 per share for the quarter.
Mallinckrodt (MNK) opened at $16.80 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.38 and a quick ratio of 1.05. Mallinckrodt has a 12-month low of $15.27 and a 12-month high of $55.32. The stock has a market cap of $1,600.00, a P/E ratio of -840.00, a PEG ratio of 0.32 and a beta of 1.04.
In other Mallinckrodt news, Director Dr Kneeland Youngblood acquired 4,560 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was acquired at an average cost of $21.94 per share, for a total transaction of $100,046.40. Following the purchase, the director now owns 19,789 shares in the company, valued at approximately $434,170.66. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.53% of the company’s stock.
MNK has been the topic of a number of analyst reports. Canaccord Genuity cut their price objective on shares of Mallinckrodt from $38.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Stifel Nicolaus lowered their target price on shares of Mallinckrodt from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Jefferies Group assumed coverage on shares of Mallinckrodt in a research note on Wednesday, November 8th. They issued a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $52.00 target price on shares of Mallinckrodt in a research note on Thursday, November 2nd. Finally, Morgan Stanley lowered their target price on shares of Mallinckrodt from $40.00 to $27.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $43.10.
WARNING: This article was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/20/mallinckrodt-mnk-to-release-quarterly-earnings-on-tuesday.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.